0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover2628.81%IV77.97%PremiumJul 26, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.0411Delta0.0046Gamma15.13Leverage Ratio-0.6086Theta0.0000Rho-0.62Eff Leverage0.0006Vega
Inovio Pharmaceuticals Stock Discussion
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet